SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

PURPOSE: Androgen deprivation therapy (ADT), an important treatment for advanced prostate cancer, is highly variable in its effectiveness. We hypothesized that genetic variants of androgen transporter genes, SLCO2B1 and SLCO1B3, may determine time to progression on ADT. PATIENTS AND METHODS: A cohor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yang, Ming, Xie, Wanling, Mostaghel, Elahe, Nakabayashi, Mari, Werner, Lillian, Sun, Tong, Pomerantz, Mark, Freedman, Matthew, Ross, Robert, Regan, Meredith, Sharifi, Nima, Figg, William Douglas, Balk, Steven, Brown, Myles, Taplin, Mary-Ellen, Oh, William K., Lee, Gwo-Shu Mary, Kantoff, Philip W.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2011
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3138634/
https://ncbi.nlm.nih.gov/pubmed/21606417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.2405
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars